Ludwig Appoints Dr. Kyle Ambert Ph.D. to Scientific Advisory Board
Ludwig (OTC PINK:LUDG) announced the appointment of Dr. Kyle H. Ambert, PhD, to its Scientific Advisory Board (SAB) effective immediately. Dr. Ambert, the current Director of Data Science at Nike, brings expertise in data analytics, machine learning, and biomedical informatics. He will act as a consultant for Ludwig and its subsidiary, mRNA for Life, Inc., aiding in the design and analysis of clinical studies. Dr. Marvin S. Hausman, Chairman of the SAB, expressed confidence in Dr. Ambert’s role in advancing cancer diagnosis and treatment through proprietary genetic biomarkers.
- Appointment of Dr. Kyle H. Ambert as a consultant and SAB member strengthens the company's expertise in data science and machine learning.
- Dr. Ambert's background can enhance research in cancer-genomic and mRNA programs, potentially improving treatment outcomes.
- None.
Insights
Analyzing...
SPARKS, NV / ACCESSWIRE / July 21, 2022 / Ludwig (OTC PINK:LUDG) is pleased to announce that Dr. Marvin S. Hausman MD, Chairman of Ludwig's Scientific Advisory Board (SAB) has appointed Dr. Kyle H. Ambert, PhD to its SAB, effective immediately. Dr.Ambert has also agreed to become a consultant to Ludwig and its subsidiary mRNA for Life, Inc. and will assist the Company in designing clinical studies and analyzing their results.
Dr. Ambert is currently Director of Data Science at Nike, Inc., and has extensive experience in data analytics, machine learning, artificial intelligence, and applied analytics. His previous experience includes postings with the National Library of Medicine and Intel Corp. Dr. Ambert holds a PhD in Biomedical Informatics from Oregon Health & Science University.
Dr. Marvin S. Hausman MD, Chairman of the Ludwig SAB commented, "I am extremely pleased to welcome Dr. Ambert to our team. Dr. Ambert's knowledge of applied machine learning and deep learning represents a major addition to the Company as we develop proprietary genetic biomarkers that may have the potential to diagnose early onset of cancer and predict response to various anticancer treatments.
"I am pleased to be asked to join Ludwig's SAB and look forward to assisting in the research, development and launch of the Company's cancer-genomic and inflammatory messenger RNA program," said Dr. Ambert.
SAFE HARBOR
Forward-looking statements in this release are made under the "safe harbor" provision of the Private Securities Litigation Reform Act of 1995. Ludwig Enterprises Inc.'s forward-looking statements are not a guarantee of future performance. This news release includes forward-looking statements concerning the future level of business for the parties. These statements are necessarily subject to risk and uncertainty. Actual results could differ materially from those projected in these forward-looking statements due to certain risk factors that could cause results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of Ludwig Enterprises, Inc., and no assurance can be given that such results will be achieved. Potential risks and uncertainties include, but are not limited to, the ability to procure, appropriately priced, retain, and complete projects and changes in products and competition.
CONTACT:
Ludwig Enterprises,
Anne Blackstone,
786-235-9026
or
SOURCE: Ludwig Enterprises, Inc.
View source version on accesswire.com:
https://www.accesswire.com/709295/Ludwig-Appoints-Dr-Kyle-Ambert-PhD-to-Scientific-Advisory-Board
FAQ
Who is Dr. Kyle H. Ambert and what is his role at Ludwig?
What experience does Dr. Ambert bring to Ludwig?
What are the expected contributions of Dr. Ambert to Ludwig?
When was Dr. Ambert's appointment announced?
